Health Technology Assessment reports published to date204No. 49A <strong>systematic</strong> review and economicmodel of the clinical and costeffectivenessof immunosuppressivetherapy <strong>for</strong> renal transplantation inchildren.By Yao G, Albon E, Adi Y, Mil<strong>for</strong>d D,Bayliss S, Ready A, et al.No. 50Amniocentesis results: investigation ofanxiety. The ARIA trial.By Hewison J, Nixon J, Fountain J,Cocks K, Jones C, Mason G, et al.Volume 11, 2007No. 1Pemetrexed disodium <strong>for</strong> the treatmentof malignant pleural mesothelioma:a <strong>systematic</strong> review and economicevaluation.By Dundar Y, Bagust A, Dickson R,Dodd S, Green J, Haycox A, et al.No. 2A <strong>systematic</strong> review and economicmodel of the clinical effectivenessand cost-effectiveness of docetaxelin combination with prednisone orprednisolone <strong>for</strong> the treatment ofhormone-refractory metastatic prostatecancer.By Collins R, Fenwick E, Trowman R,Perard R, Norman G, Light K, et al.No. 3A <strong>systematic</strong> review of rapid diagnostictests <strong>for</strong> the detection of tuberculosisinfection.By Dinnes J, Deeks J, Kunst H,Gibson A, Cummins E, Waugh N, et al.No. 4The clinical effectiveness and costeffectivenessof strontium ranelate <strong>for</strong>the prevention of osteoporotic fragilityfractures in postmenopausal women.By Stevenson M, Davis S, Lloyd-JonesM, Beverley C.No. 5A <strong>systematic</strong> review of quantitative andqualitative research on the role andeffectiveness of written in<strong>for</strong>mationavailable to patients about individualmedicines.By Raynor DK, BlenkinsoppA, Knapp P, Grime J, Nicolson DJ,Pollock K, et al.No. 6Oral naltrexone as a treatment <strong>for</strong>relapse prevention in <strong>for</strong>merly opioiddependentdrug users: a <strong>systematic</strong>review and economic evaluation.By Adi Y, Juarez-Garcia A, Wang D,Jowett S, Frew E, Day E, et al.No. 7Glucocorticoid-induced osteoporosis:a <strong>systematic</strong> review and cost–utilityanalysis.By Kanis JA, Stevenson M,McCloskey EV, Davis S, Lloyd-Jones M.No. 8Epidemiological, social, diagnostic andeconomic evaluation of populationscreening <strong>for</strong> genital chlamydialinfection.By Low N, McCarthy A, Macleod J,Salisbury C, Campbell R, Roberts TE,et al.No. 9Methadone and buprenorphine <strong>for</strong> themanagement of opioid dependence:a <strong>systematic</strong> review and economicevaluation.By Connock M, Juarez-Garcia A,Jowett S, Frew E, Liu Z, Taylor RJ, et al.No. 10Exercise Evaluation RandomisedTrial (EXERT): a randomised trialcomparing GP referral <strong>for</strong> leisurecentre-based exercise, community-basedwalking and advice only.By Isaacs AJ, Critchley JA, See TaiS, Buckingham K, Westley D, HarridgeSDR, et al.No. 11Interferon alfa (pegylated and nonpegylated)and ribavirin <strong>for</strong> thetreatment of mild chronic hepatitisC: a <strong>systematic</strong> review and economicevaluation.By Shepherd J, Jones J, Hartwell D,Davidson P, Price A, Waugh N.No. 12Systematic review and economicevaluation of bevacizumab andcetuximab <strong>for</strong> the treatment ofmetastatic colorectal cancer.By Tappenden P, Jones R, Paisley S,Carroll C.No. 13A <strong>systematic</strong> review and economicevaluation of epoetin alfa, epoetinbeta and darbepoetin alfa in anaemiaassociated with cancer, especially thatattributable to cancer treatment.By Wilson J, Yao GL, Raftery J,Bohlius J, Brunskill S, Sandercock J,et al.No. 14A <strong>systematic</strong> review and economicevaluation of statins <strong>for</strong> the preventionof coronary events.By Ward S, Lloyd Jones M, Pandor A,Holmes M, Ara R, Ryan A, et al.No. 15A <strong>systematic</strong> review of the effectivenessand cost-effectiveness of differentmodels of community-based respitecare <strong>for</strong> frail older people and theircarers.By Mason A, Weatherly H, SpilsburyK, Arksey H, Golder S, Adamson J, et al.No. 16Additional therapy <strong>for</strong> youngchildren with spastic cerebral palsy: arandomised controlled trial.By Weindling AM, Cunningham CC,Glenn SM, Edwards RT, Reeves DJ.No. 17Screening <strong>for</strong> type 2 diabetes: literaturereview and economic modelling.By Waugh N, Scotland G, McNameeP, Gillett M, Brennan A, Goyder E, et al.No. 18The effectiveness and cost-effectivenessof cinacalcet <strong>for</strong> secondaryhyperparathyroidism in end-stage renaldisease patients on dialysis: a <strong>systematic</strong>review and economic evaluation.By Garside R, Pitt M, Anderson R,Mealing S, Roome C, Snaith A, et al.No. 19The clinical effectiveness and costeffectivenessof gemcitabine <strong>for</strong>metastatic breast cancer: a <strong>systematic</strong>review and economic evaluation.By Takeda AL, Jones J, Loveman E,Tan SC, Clegg AJ.No. 20A <strong>systematic</strong> review of duplexultrasound, magnetic resonanceangiography and computedtomography angiography <strong>for</strong>the diagnosis and assessment ofsymptomatic, lower limb peripheralarterial disease.By Collins R, Cranny G, Burch J,Aguiar-Ibáñez R, Craig D, Wright K,et al.No. 21The clinical effectiveness and costeffectivenessof treatments <strong>for</strong> childrenwith idiopathic steroid-resistantnephrotic syndrome: a <strong>systematic</strong>review.By Colquitt JL, Kirby J, Green C,Cooper K, Trompeter RS.No. 22A <strong>systematic</strong> review of the routinemonitoring of growth in children ofprimary school age to identify growthrelatedconditions.By Fayter D, Nixon J, Hartley S,Rithalia A, Butler G, Rudolf M, et al.No. 23Systematic review of the effectiveness ofpreventing and treating Staphylococcusaureus carriage in reducing peritonealcatheter-related infections.By McCormack K, Rabindranath K,Kilonzo M, Vale L, Fraser C, McIntyre L,et al.
DOI: 10.3310/hta13480 Health Technology Assessment 2009; Vol. 13: No. 48No. 24The clinical effectiveness and costof repetitive transcranial magneticstimulation versus electroconvulsivetherapy in severe depression: amulticentre pragmatic randomisedcontrolled trial and economic analysis.By McLoughlin DM, Mogg A, ErantiS, Pluck G, Purvis R, Edwards D, et al.No. 25A randomised controlled trial andeconomic evaluation of direct versusindirect and individual versus groupmodes of speech and language therapy<strong>for</strong> children with primary languageimpairment.By Boyle J, McCartney E, Forbes J,O’Hare A.No. 26Hormonal therapies <strong>for</strong> early breastcancer: <strong>systematic</strong> review and economicevaluation.By Hind D, Ward S, De Nigris E,Simpson E, Carroll C, Wyld L.No. 27Cardioprotection against the toxiceffects of anthracyclines given tochildren with cancer: a <strong>systematic</strong>review.By Bryant J, Picot J, Levitt G,Sullivan I, Baxter L, Clegg A.No. 28Adalimumab, etanercept and infliximab<strong>for</strong> the treatment of ankylosingspondylitis: a <strong>systematic</strong> review andeconomic evaluation.By McLeod C, Bagust A, Boland A,Dagenais P, Dickson R, Dundar Y, et al.No. 29Prenatal screening and treatmentstrategies to prevent group Bstreptococcal and other bacterialinfections in early infancy: costeffectivenessand expected value ofin<strong>for</strong>mation analyses.By Colbourn T, Asseburg C, Bojke L,Philips Z, Claxton K, Ades AE, et al.No. 30Clinical effectiveness and costeffectivenessof bone morphogeneticproteins in the non-healing of fracturesand spinal fusion: a <strong>systematic</strong> review.By Garrison KR, Donell S, Ryder J,Shemilt I, Mug<strong>for</strong>d M, Harvey I, et al.No. 31A randomised controlled trial ofpostoperative radiotherapy followingbreast-conserving surgery in aminimum-risk older population. ThePRIME trial.By Prescott RJ, Kunkler IH, WilliamsLJ, King CC, Jack W, van der Pol M,et al.No. 32Current practice, accuracy, effectivenessand cost-effectiveness of the schoolentry hearing screen.By Bam<strong>for</strong>d J, Fortnum H, BristowK, Smith J, Vamvakas G, Davies L, et al.No. 33The clinical effectiveness and costeffectivenessof inhaled insulin indiabetes mellitus: a <strong>systematic</strong> reviewand economic evaluation.By Black C, Cummins E, Royle P,Philip S, Waugh N.No. 34Surveillance of cirrhosis <strong>for</strong>hepatocellular carcinoma: <strong>systematic</strong>review and economic analysis.By Thompson Coon J, Rogers G,Hewson P, Wright D, Anderson R,Cramp M, et al.No. 35The Birmingham RehabilitationUptake Maximisation Study (BRUM).Homebased compared with hospitalbasedcardiac rehabilitation in a multiethnicpopulation: cost-effectivenessand patient adherence.By Jolly K, Taylor R, Lip GYH,Greenfield S, Raftery J, Mant J, et al.No. 36A <strong>systematic</strong> review of the clinical,public health and cost-effectiveness ofrapid diagnostic tests <strong>for</strong> the detectionand identification of bacterial intestinalpathogens in faeces and food.By Abubakar I, Irvine L, Aldus CF,Wyatt GM, Fordham R, Schelenz S, et al.No. 37A randomised controlled trialexamining the longer-term outcomesof standard versus new antiepilepticdrugs. The SANAD trial.By Marson AG, Appleton R, BakerGA, Chadwick DW, Doughty J, Eaton B,et al.No. 38Clinical effectiveness and costeffectivenessof different modelsof managing long-term oral anticoagulationtherapy: a <strong>systematic</strong>review and economic modelling.By Connock M, Stevens C, Fry-SmithA, Jowett S, Fitzmaurice D, Moore D,et al.No. 39A <strong>systematic</strong> review and economicmodel of the clinical effectivenessand cost-effectiveness of interventions<strong>for</strong> preventing relapse in people withbipolar disorder.By Soares-Weiser K, Bravo Vergel Y,Beynon S, Dunn G, Barbieri M, Duffy S,et al.No. 40Taxanes <strong>for</strong> the adjuvant treatment ofearly breast cancer: <strong>systematic</strong> reviewand economic evaluation.By Ward S, Simpson E, Davis S, HindD, Rees A, Wilkinson A.No. 41The clinical effectiveness and costeffectivenessof screening <strong>for</strong> openangle glaucoma: a <strong>systematic</strong> reviewand economic evaluation.By Burr JM, Mowatt G, HernándezR, Siddiqui MAR, Cook J, Lourenco T,et al.No. 42Acceptability, benefit and costs of earlyscreening <strong>for</strong> hearing disability: a studyof potential screening tests and models.By Davis A, Smith P, Ferguson M,Stephens D, Gianopoulos I.No. 43Contamination in trials of educationalinterventions.By Keogh-Brown MR, BachmannMO, Shepstone L, Hewitt C, Howe A,Ramsay CR, et al.No. 44Overview of the clinical effectiveness ofpositron emission tomography imagingin selected cancers.By Facey K, Bradbury I, Laking G,Payne E.No. 45The effectiveness and cost-effectivenessof carmustine implants andtemozolomide <strong>for</strong> the treatment ofnewly diagnosed high-grade glioma:a <strong>systematic</strong> review and economicevaluation.By Garside R, Pitt M, Anderson R,Rogers G, Dyer M, Mealing S, et al.No. 46Drug-eluting <strong>stents</strong>: a <strong>systematic</strong> reviewand economic evaluation.By Hill RA, Boland A, Dickson R,Dündar Y, Haycox A, McLeod C, et al.No. 47The clinical effectiveness andcost-effectiveness of cardiacresynchronisation (biventricular pacing)<strong>for</strong> heart failure: <strong>systematic</strong> review andeconomic model.By Fox M, Mealing S, Anderson R,Dean J, Stein K, Price A, et al.No. 48Recruitment to randomised trials:strategies <strong>for</strong> trial enrolment andparticipation study. The STEPS study.By Campbell MK, Snowdon C,Francis D, Elbourne D, McDonald AM,Knight R, et al.205© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
- Page 1 and 2:
Health Technology Assessment 2009;
- Page 3 and 4:
Endovascular stents for abdominal a
- Page 5:
DOI: 10.3310/hta13480 Health Techno
- Page 9 and 10:
DOI: 10.3310/hta13480 Health Techno
- Page 11 and 12:
DOI: 10.3310/hta13480 Health Techno
- Page 13:
DOI: 10.3310/hta13480 Health Techno
- Page 16 and 17:
Executive summaryxivResultsClinical
- Page 19 and 20:
DOI: 10.3310/hta13480 Health Techno
- Page 21 and 22:
DOI: 10.3310/hta13480 Health Techno
- Page 23:
DOI: 10.3310/hta13480 Health Techno
- Page 27 and 28:
DOI: 10.3310/hta13480 Health Techno
- Page 29 and 30:
DOI: 10.3310/hta13480 Health Techno
- Page 31 and 32:
DOI: 10.3310/hta13480 Health Techno
- Page 33 and 34:
DOI: 10.3310/hta13480 Health Techno
- Page 35 and 36:
DOI: 10.3310/hta13480 Health Techno
- Page 37 and 38:
DOI: 10.3310/hta13480 Health Techno
- Page 39 and 40:
DOI: 10.3310/hta13480 Health Techno
- Page 41 and 42:
DOI: 10.3310/hta13480 Health Techno
- Page 43 and 44:
DOI: 10.3310/hta13480 Health Techno
- Page 45 and 46:
DOI: 10.3310/hta13480 Health Techno
- Page 47 and 48:
DOI: 10.3310/hta13480 Health Techno
- Page 49 and 50:
DOI: 10.3310/hta13480 Health Techno
- Page 51 and 52:
DOI: 10.3310/hta13480 Health Techno
- Page 53 and 54:
DOI: 10.3310/hta13480 Health Techno
- Page 55:
DOI: 10.3310/hta13480 Health Techno
- Page 58 and 59:
Assessment of clinical effectivenes
- Page 60 and 61:
Assessment of clinical effectivenes
- Page 62 and 63:
Assessment of clinical effectivenes
- Page 64:
Assessment of clinical effectivenes
- Page 67 and 68:
DOI: 10.3310/hta13480 Health Techno
- Page 69 and 70:
DOI: 10.3310/hta13480 Health Techno
- Page 71 and 72:
DOI: 10.3310/hta13480 Health Techno
- Page 73 and 74:
DOI: 10.3310/hta13480 Health Techno
- Page 75 and 76:
DOI: 10.3310/hta13480 Health Techno
- Page 77 and 78:
DOI: 10.3310/hta13480 Health Techno
- Page 79 and 80:
DOI: 10.3310/hta13480 Health Techno
- Page 81 and 82:
DOI: 10.3310/hta13480 Health Techno
- Page 83 and 84:
DOI: 10.3310/hta13480 Health Techno
- Page 85 and 86:
DOI: 10.3310/hta13480 Health Techno
- Page 87 and 88:
DOI: 10.3310/hta13480 Health Techno
- Page 89 and 90:
DOI: 10.3310/hta13480 Health Techno
- Page 91 and 92:
DOI: 10.3310/hta13480 Health Techno
- Page 93:
DOI: 10.3310/hta13480 Health Techno
- Page 96 and 97:
Assessment of cost-effectiveness ev
- Page 98 and 99:
Assessment of cost-effectiveness ev
- Page 100 and 101:
Assessment of cost-effectiveness ev
- Page 102 and 103:
Assessment of cost-effectiveness ev
- Page 104 and 105:
Assessment of cost-effectiveness ev
- Page 106 and 107:
Assessment of cost-effectiveness ev
- Page 108 and 109:
Assessment of cost-effectiveness ev
- Page 110 and 111:
Assessment of cost-effectiveness ev
- Page 112 and 113:
Assessment of cost-effectiveness ev
- Page 114 and 115:
Assessment of cost-effectiveness ev
- Page 116 and 117:
Assessment of cost-effectiveness ev
- Page 118 and 119:
Assessment of cost-effectiveness ev
- Page 120 and 121:
Assessment of cost-effectiveness ev
- Page 122 and 123:
Assessment of cost-effectiveness ev
- Page 124 and 125:
Assessment of cost-effectiveness ev
- Page 126 and 127:
Assessment of cost-effectiveness ev
- Page 128 and 129:
Assessment of cost-effectiveness ev
- Page 130 and 131:
Assessment of cost-effectiveness ev
- Page 132 and 133:
Assessment of cost-effectiveness ev
- Page 134 and 135:
Assessment of cost-effectiveness ev
- Page 136 and 137:
Assessment of cost-effectiveness ev
- Page 138 and 139:
Assessment of cost-effectiveness ev
- Page 140 and 141:
Assessment of cost-effectiveness ev
- Page 142 and 143:
Assessment of cost-effectiveness ev
- Page 144 and 145:
Assessment of cost-effectiveness ev
- Page 146 and 147:
Assessment of cost-effectiveness ev
- Page 148 and 149:
Assessment of cost-effectiveness ev
- Page 150 and 151:
Assessment of cost-effectiveness ev
- Page 152 and 153:
Assessment of cost-effectiveness ev
- Page 155:
DOI: 10.3310/hta13480 Health Techno
- Page 158 and 159:
Discussion140We attempted to obtain
- Page 160 and 161:
Discussionevaluation to date of pol
- Page 162 and 163:
Conclusions• Opportunities for in
- Page 165 and 166:
DOI: 10.3310/hta13480 Health Techno
- Page 167 and 168:
DOI: 10.3310/hta13480 Health Techno
- Page 169 and 170:
DOI: 10.3310/hta13480 Health Techno
- Page 171 and 172: DOI: 10.3310/hta13480 Health Techno
- Page 173 and 174: DOI: 10.3310/hta13480 Health Techno
- Page 175 and 176: DOI: 10.3310/hta13480 Health Techno
- Page 177 and 178: DOI: 10.3310/hta13480 Health Techno
- Page 179: DOI: 10.3310/hta13480 Health Techno
- Page 182 and 183: Appendix 1164S28 16 RETA/TI,ABS29 0
- Page 184 and 185: Appendix 116650. (EUROSTAR and (eva
- Page 186 and 187: Appendix 116844. endovascular repai
- Page 188 and 189: Appendix 1MEDLINEVia OvidSearched 1
- Page 190 and 191: Appendix 2TABLE 75 Checklist for Pa
- Page 192 and 193: Appendix 2TABLE 76 Checklist for Bo
- Page 194 and 195: Appendix 2TABLE 77 Checklist for Mi
- Page 196 and 197: Appendix 2TABLE 78 Checklist for Ep
- Page 198 and 199: Appendix 2TABLE 79 Checklist for Pr
- Page 200 and 201: Appendix 2TABLE 80 Checklist for Me
- Page 202 and 203: Appendix 2TABLE 81 Checklist for EV
- Page 205 and 206: DOI: 10.3310/hta13480 Health Techno
- Page 207: DOI: 10.3310/hta13480 Health Techno
- Page 210 and 211: Health Technology Assessment report
- Page 212 and 213: Health Technology Assessment report
- Page 214 and 215: Health Technology Assessment report
- Page 216 and 217: Health Technology Assessment report
- Page 218 and 219: Health Technology Assessment report
- Page 220 and 221: Health Technology Assessment report
- Page 224 and 225: Health Technology Assessment report
- Page 226 and 227: Health Technology Assessment report
- Page 228 and 229: Health Technology Assessment report
- Page 230 and 231: Health Technology Assessment progra
- Page 232 and 233: Health Technology Assessment progra
- Page 234: FeedbackThe HTA programme and the a